| Summary: | Biological agents are used to treat psoriasis in patients who do not respond to conventional systemic therapies such as cyclosporine, acitretin, methotrexate, phototherapy/photochemotherapy, or for whom these therapies are contraindicated. Patients who will use these agents are selected based on the eligibility criteria for biological agents. Patients are assessed at regular intervals with relevant laboratory parameters before and during the treatment. Patients should be assessed particularly for tuberculosis, malignancies, congestive heart failure, demyelinating diseases, and infections. All necessary vaccinations should be completed before starting the treatment, if possible. Live vaccines should be avoided during the treatment, and patients who require surgical intervention should be assessed for postoperative infection risk on a case-tocase basis, and the treatment should be suspended if deemed necessary.
|
|---|